암 진단 시장 예측(-2031년) : 제품, 기술, 유형, 용도, 최종사용자, 지역별

The cancer diagnostics market is projected to reach USD 44.92 billion by 2031 from USD 29.86 billion in 2026, registering a CAGR of 7.0%.

Cancer diagnostics play a critical role in oncology by enabling early detection, accurate diagnosis, disease characterization, treatment selection, and ongoing monitoring of cancer. The cancer diagnostics market, segmented by product, comprises a broad portfolio of instruments and consumables used across in vitro diagnostics (IVD), anatomic pathology, and imaging-based diagnostics. Market growth is driven by the increasing adoption of advanced diagnostic technologies, sustained demand for consumables, rising global cancer incidence, expanding screening initiatives, and growing diagnostic testing volumes.

The market encompasses a wide range of diagnostic technologies, including PCR, immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, histopathology, biopsy, CT, MRI, PET, mammography, and ultrasound. These technologies are used to diagnose both solid tumors and hematological malignancies, supporting applications such as cancer screening, early detection, disease diagnosis and characterization, treatment decision-making, and disease monitoring, including recurrence detection.

Based on product, the cancer diagnostics market is segmented into IVD testing, anatomic pathology, and imaging-based diagnostics. Among these, IVD testing accounted for the largest market share and is projected to witness the fastest growth during the forecast period. The segment's dominance is driven by the increasing global burden of cancer, growing emphasis on early detection and precision oncology, rising adoption of liquid biopsy and molecular diagnostic technologies, and expanding use of biomarker-based testing for cancer screening, diagnosis, treatment selection, and disease monitoring. Continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, companion diagnostics, and AI-enabled diagnostic platforms have significantly enhanced diagnostic accuracy, sensitivity, and turnaround time. Supported by increasing healthcare investments, favorable reimbursement for molecular testing, government-led cancer screening initiatives, and expanding access to personalized medicine, the IVD testing segment is expected to maintain its leading position in the global cancer diagnostics market throughout the forecast period.

Based on end user, the cancer diagnostics market is segmented into hospitals and clinical laboratories. Among these, hospitals account for the largest market share due to their high patient volumes, comprehensive diagnostic infrastructure, and ability to provide integrated cancer care encompassing screening, diagnosis, treatment planning, and disease monitoring under a single setting. Hospitals are the primary centers for advanced imaging, biopsy procedures, molecular testing, and multidisciplinary oncology care, driving significant demand for cancer diagnostic services. The increasing adoption of precision oncology, companion diagnostics, next-generation sequencing (NGS), and AI-enabled diagnostic workflows, coupled with rising investments in hospital-based cancer centers and expanding access to advanced diagnostic technologies, continues to strengthen the dominance of the hospital segment. Furthermore, growing government initiatives for cancer screening, increasing cancer admissions, and the integration of digital pathology and laboratory information systems are reinforcing the leading position of hospitals in the global cancer diagnostics market, while clinical laboratories continue to witness steady growth driven by increasing outsourcing of specialized molecular and genomic testing.

Based on region, the cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest market share in 2025 and continues to serve as the primary market driver, supported by its advanced healthcare infrastructure, high healthcare expenditure, favorable reimbursement policies, and early adoption of innovative cancer diagnostic technologies. The region has a high prevalence of cancer, well-established screening programs, and increasing demand for early detection and precision oncology, resulting in the widespread adoption of molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, digital pathology, and advanced imaging technologies across hospitals, cancer centers, and clinical laboratories. The strong presence of leading diagnostics companies, continuous technological advancements, substantial investments in oncology research, supportive regulatory frameworks, and expanding integration of artificial intelligence into cancer diagnostics further reinforce North America's market leadership.

A breakdown of the primary respondents (supply-side) for the cancer diagnostics market referred to in this report is provided below:

• By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
• By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
• By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6% and Middle East & Africa: 3%

Prominent players in the cancer diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Exact Sciences Corporation (US), Guardant Health, Inc. (US), Sysmex Corporation (Japan), Foundation Medicine, Inc. (US), Myriad Genetics, Inc. (US), NeoGenomics Laboratories, Inc. (US), bioMerieux SA (France), and Revvity, Inc. (US), among others.

Research Coverage

The report evaluates the cancer diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist market leaders and new entrants in the cancer diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights into better positioning their businesses and developing effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the cancer diagnostics market.

This report provides insights into the following points:

• Analysis of Key Drivers (Increasing global burden of cancer driven by aging populations, lifestyle changes, and environmental risk factors; Growing emphasis on early cancer detection and screening to improve patient outcomes and survival rates; Advancements in molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, and companion diagnostics enabling precision oncology; Rising adoption of AI-powered imaging and digital pathology solutions to enhance diagnostic accuracy and workflow efficiency; Increasing investments in cancer research, biomarker discovery, and personalized medicine), restraints (High cost of advanced diagnostic technologies and genomic testing; Limited accessibility to sophisticated diagnostic infrastructure in low- and middle-income countries; Stringent regulatory approval and reimbursement challenges; Complexity in interpreting genomic and molecular data requiring specialized expertise), opportunities (Growing demand for non-invasive diagnostic techniques such as liquid biopsy; Expansion of national cancer screening programs and awareness initiatives; Increasing adoption of precision medicine and companion diagnostics; Rising investments in AI-enabled diagnostics, digital pathology, and multi-cancer early detection (MCED) tests; Growing healthcare infrastructure and diagnostic capabilities in emerging markets), and challenges (Shortage of skilled oncology and pathology professionals; Data privacy, interoperability, and integration issues with digital diagnostic platforms; High validation requirements for novel biomarkers and diagnostic assays; Reimbursement variability across different healthcare systems; Ensuring equitable access to advanced cancer diagnostics while maintaining affordability and diagnostic accuracy).
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the cancer diagnostics market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product, type, application, technology, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the cancer diagnostics market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the cancer diagnostics market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CANCER DIAGNOSTICS MARKET OVERVIEW
• 3.2 ASIA PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY AND TECHNOLOGY
• 3.3 CANCER DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH (2026-2031)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing incidence of cancer
    • 4.2.1.2 Growth in number of private diagnostics centers
    • 4.2.1.3 Availability of favorable reimbursement policies
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High capital investment requirements
    • 4.2.2.2 High cost of advanced diagnostic imaging systems
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing adoption of companion diagnostics
    • 4.2.3.2 Expansion of organized cancer screening programs
    • 4.2.3.3 Growing demand for cancer diagnostics in emerging markets
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Increasing adoption of refurbished diagnostic imaging systems
    • 4.2.4.2 Shortage of skilled professionals
    • 4.2.4.3 Limited healthcare infrastructure and low awareness in developing countries
    • 4.2.4.4 Product recalls and diagnostic test failures
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN CANCER DIAGNOSTICS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 INVESTMENT AND FUNDING SCENARIO
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE BY PRODUCT
  • 5.6.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
  • 5.6.3 AVERAGE SELLING PRICE, BY REGION
    • 5.6.3.1 Average selling price of glucose monitoring test strips, by region
    • 5.6.3.2 Average selling price of infectious disease testing products, by region
    • 5.6.3.3 Average selling price of cardiometabolic monitoring products, by region
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 PRICE IMPACT ANALYSIS
  • 5.9.2 IMPACT ON REGION
    • 5.9.2.1 North America
    • 5.9.2.2 Europe
    • 5.9.2.3 Asia Pacific

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 IVD TESTING
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Molecular diagnostics
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Biochemical technologies
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 LIST OF MAJOR PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GENERATIVE AI ON CANCER DIAGNOSTICS MARKET
  • 6.5.1 INTRODUCTION
  • 6.5.2 TOP USE CASES AND MARKET POTENTIAL
  • 6.5.3 KEY COMPANIES IMPLEMENTING AI
  • 6.5.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CANCER DIAGNOSTICS
    • 7.2.1.1 Eco-friendly Initiatives
• 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS OF VARIOUS END USERS
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 CANCER DIAGNOSTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 SCREENING & EARLY DETECTION
  • 9.2.1 INCREASING EMPHASIS ON EARLY CANCER DETECTION TO DRIVE SEGMENT
• 9.3 DIAGNOSIS & DISEASE CHARACTERIZATION
  • 9.3.1 GOVERNMENT INITIATIVES TO EXPAND HEALTHCARE ACCESS TO DRIVE SEGMENT
• 9.4 TREATMENT DECISION SUPPORT
  • 9.4.1 RISING DEMAND FOR PRECISION ONCOLOGY TO PROPEL SEGMENT
• 9.5 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT
  • 9.5.1 INCREASING DEMAND FOR DETECTION OF DISEASE PROGRESSION SUPPORT SEGMENT GROWTH
• 9.6 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION
  • 9.6.1 GROWING EMPHASIS ON POST-TREATMENT MONITORING TO DRIVE SEGMENT

10 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 IVD TESTING
  • 10.2.1 POLYMERASE CHAIN REACTION
    • 10.2.1.1 PCR-based diagnostic tests preferred as they provide simple representations of genomic data
  • 10.2.2 IN SITU HYBRIDIZATION
    • 10.2.2.1 ISH used for identification of specific mRNA species within sample cells
  • 10.2.3 IMMUNOHISTOCHEMISTRY
    • 10.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
  • 10.2.4 NEXT-GENERATION SEQUENCING
    • 10.2.4.1 NGS dominates IVD testing market
  • 10.2.5 IMMUNOASSAY
    • 10.2.5.1 Immunoassay segment accounted for second-largest share of cancer diagnostics market for IVD testing
  • 10.2.6 MICROARRAY
    • 10.2.6.1 Cost-effectiveness of microarray technology to support market growth
  • 10.2.7 FLOW CYTOMETRY
    • 10.2.7.1 Limited budgets restrain segment growth
  • 10.2.8 OTHER IVD TECHNOLOGIES
• 10.3 IMAGING TECHNOLOGIES
  • 10.3.1 MAGNETIC RESONANCE IMAGING
    • 10.3.1.1 Technological advancements to boost segment growth
  • 10.3.2 COMPUTED TOMOGRAPHY
    • 10.3.2.1 CT is widely used technique in cancer diagnostics
  • 10.3.3 POSITRON EMISSION TOMOGRAPHY (PET)
    • 10.3.3.1 Widely used nuclear imaging technique in cancer diagnostics
  • 10.3.4 MAMMOGRAPHY
    • 10.3.4.1 Increasing government initiatives for breast cancer screening to drive segment growth
  • 10.3.5 ULTRASOUND
    • 10.3.5.1 Substantial clinical advancements and technical innovations to support market growth
• 10.4 ANATOMIC PATHOLOGY
  • 10.4.1 INTRODUCTION
    • 10.4.1.1 Histopathology
      • 10.4.1.1.1 Growing demand for high-throughput, error-free staining to drive market
    • 10.4.1.2 Cytopathology
      • 10.4.1.2.1 Rising cervical cancer screening volumes to boost demand for automated cytology systems
• 10.5 BIOPSIES

11 CANCER DIAGNOSTICS MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 SOLID TUMORS
• 11.3 BREAST CANCER
  • 11.3.1 SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
• 11.4 LUNG CANCER
  • 11.4.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-LARGEST SHARE
• 11.5 COLORECTAL CANCER
  • 11.5.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO DRIVE MARKET GROWTH
• 11.6 GASTRIC CANCER
  • 11.6.1 SEGMENT GROWTH SUPPORTED BY INCREASING ADOPTION OF BIOMARKER-BASED TESTING FOR TREATMENT SELECTION
• 11.7 HEAD & NECK CANCER
  • 11.7.1 SEGMENT TO BE DRIVEN BY INCREASING AGING POPULATION
• 11.8 PROSTATE CANCER
  • 11.8.1 RISING GLOBAL DISEASE BURDEN AND EVOLVING DIAGNOSTIC LANDSCAPE TO BOOST SEGMENT
• 11.9 CERVICAL CANCER
  • 11.9.1 INCREASE IN SCREENING, HPV TESTING, AND BIOMARKER ADOPTION TO DRIVE MARKET GROWTH
• 11.10 MELANOMA
  • 11.10.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH
  • 11.10.2 OTHER SOLID TUMORS
• 11.11 LIQUID TUMORS
• 11.12 LEUKEMIA
  • 11.12.1 SEGMENT CONTINUES TO REPRESENT SIGNIFICANT SHARE OF GLOBAL HEMATOLOGIC (LIQUID) CANCER BURDEN
• 11.13 MYELOMA
  • 11.13.1 RISING CASES, PARTICULARLY ACROSS ASIA AND AFRICA, TO DRIVE MARKET
• 11.14 LYMPHOMA
  • 11.14.1 INCREASING DISEASE BURDEN TO DRIVE SEGMENT

12 CANCER DIAGNOSTICS MARKET, BY PRODUCT

• 12.1 INTRODUCTION
• 12.2 IVD TESTING
  • 12.2.1 KITS & REAGENTS
    • 12.2.1.1 Increasing adoption due to ease of use to boost segment
  • 12.2.2 INSTRUMENTS
    • 12.2.2.1 PCR instruments
      • 12.2.2.1.1 Cost-effectiveness drives growth of segment
    • 12.2.2.2 NGS instruments
      • 12.2.2.2.1 NGS is an emerging technology for cancer diagnostics
    • 12.2.2.3 Microarrays
      • 12.2.2.3.1 Use in determination of primary sites in metastatic carcinomas to boost market
  • 12.2.3 IN SITU HYBRIDIZATION
    • 12.2.3.1 Use for identification of specific mRNA species within sample cells - key driver
  • 12.2.4 IMMUNOHISTOCHEMISTRY
    • 12.2.4.1 Increasing use of IHC tests for cancer diagnostics to boost market growth
  • 12.2.5 IMMUNOASSAY
    • 12.2.5.1 Segment holds second-largest share of cancer diagnostics market for IVD testing
  • 12.2.6 FLOW CYTOMETRY
    • 12.2.6.1 Use across diagnosis, monitoring, and treatment to propel market
  • 12.2.7 OTHER IVD TESTING INSTRUMENTS
• 12.3 ANATOMIC PATHOLOGY
  • 12.3.1 INTRODUCTION
  • 12.3.2 INSTRUMENTS
    • 12.3.2.1 Slide staining systems
      • 12.3.2.1.1 Increasing focus on automation to drive market
    • 12.3.2.2 Tissue processing systems
      • 12.3.2.2.1 Use in automatic processing of tissue samples to boost market
    • 12.3.2.3 Cell processors
      • 12.3.2.3.1 Used to remove unwanted matter from cytology samples
    • 12.3.2.4 Microtomes
      • 12.3.2.4.1 Segment gaining traction as rising biopsy volumes and automation drive demand
    • 12.3.2.5 Embedding systems
      • 12.3.2.5.1 Automated tissue embedding gains momentum in cancer diagnostics
    • 12.3.2.6 Cover slippers
      • 12.3.2.6.1 Automated cover slippers strengthen workflow efficiency in cancer diagnostics
    • 12.3.2.7 Digital pathology scanners
      • 12.3.2.7.1 Shift toward automated cancer diagnostics to accelerate segment growth
    • 12.3.2.8 Other anatomic pathology instruments
  • 12.3.3 CONSUMABLES
    • 12.3.3.1 Antibodies
      • 12.3.3.1.1 Cancer diagnostic consumables market
    • 12.3.3.2 Kits & Reagents
      • 12.3.3.2.1 Use of kits is increasing among end users owing to their ease of use
    • 12.3.3.3 Probes
      • 12.3.3.3.1 Probes Enable Precise Molecular Detection in Cancer Diagnostics
    • 12.3.3.4 Other consumables
• 12.4 IMAGING-BASED
  • 12.4.1 INSTRUMENTS
    • 12.4.1.1 CT systems
      • 12.4.1.1.1 Technological advancements to drive growth of segment
    • 12.4.1.2 Ultrasound systems
      • 12.4.1.2.1 Increasing incidence of cancer to drive segment growth
  • 12.4.2 MRI SYSTEMS
    • 12.4.2.1 Rising cancer incidence and growing adoption of MRI drive market growth
    • 12.4.2.2 Mammography systems
      • 12.4.2.2.1 Increasing incidence of breast cancer to drive growth of segment
    • 12.4.2.3 PET-CT
      • 12.4.2.3.1 Technological advancements in nuclear imaging systems to drive segment
  • 12.4.3 CONSUMABLES
    • 12.4.3.1 Contrast agents
      • 12.4.3.1.1 Increasing incidence of cancer to drive segment
    • 12.4.3.2 Radiopharmaceuticals
      • 12.4.3.2.1 Increasing availability of radioisotopes to drive segment

13 CANCER DIAGNOSTICS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS & CLINICS
  • 13.2.1 SEGMENT IS LARGEST END USER OF CANCER DIAGNOSTIC PRODUCTS
• 13.3 DIAGNOSTIC LABORATORIES
  • 13.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH

14 CANCER DIAGNOSTICS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 Expected to be dominant in North American market
  • 14.2.2 CANADA
    • 14.2.2.1 High cancer burden, aging population, and expanding screening programs to support market growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
  • 14.3.2 UK
    • 14.3.2.1 Favorable government initiatives to drive market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Increasing government funding for cancer diagnosis and prevention to support market growth
  • 14.3.4 ITALY
    • 14.3.4.1 High incidence of cancer to support market growth
  • 14.3.5 SPAIN
    • 14.3.5.1 High incidence of chronic diseases to drive market growth
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Increasing healthcare expenditure to drive market growth
  • 14.4.2 JAPAN
    • 14.4.2.1 Advanced healthcare infrastructure to support market growth
  • 14.4.3 INDIA
    • 14.4.3.1 Expanding healthcare sector in country to drive market growth
  • 14.4.4 SOUTH KOREA
    • 14.4.4.1 Focus on genomic research and precision medicine to boost market growth
  • 14.4.5 AUSTRALIA
  • 14.4.6 REST OF ASIA PACIFIC
  • 14.4.7 LATIN AMERICA
    • 14.4.7.1 Increasing number of cancer screening programs to support market growth
  • 14.4.8 BRAZIL
    • 14.4.8.1 Expansion of cancer screening programs to support market growth
  • 14.4.9 MEXICO
    • 14.4.9.1 Increasing cancer screening initiatives and diagnostic infrastructure to drive market growth
  • 14.4.10 REST OF LATIN AMERICA
  • 14.4.11 MIDDLE EAST & AFRICA
    • 14.4.11.1 Increasing incidence of cancer to drive market growth

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER DIAGNOSTICS MARKET
• 15.3 REVENUE ANALYSIS, 2023-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY VALUATION AND FINANCIAL METRICS
• 15.6 BRAND/PRODUCT COMPARISON
  • 15.6.1 ABBOTT
  • 15.6.2 F. HOFFMANN-LA ROCHE LTD.
  • 15.6.3 DANAHER
• 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.7.1 STARS
  • 15.7.2 EMERGING LEADERS
  • 15.7.3 PERVASIVE PLAYERS
  • 15.7.4 PARTICIPANTS
  • 15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
    • 15.7.5.1 Company footprint
    • 15.7.5.2 Region footprint
    • 15.7.5.3 End user footprint
    • 15.7.5.4 Product footprint
    • 15.7.5.5 Technology footprint
• 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 15.8.1 PROGRESSIVE COMPANIES
  • 15.8.2 RESPONSIVE COMPANIES
  • 15.8.3 DYNAMIC COMPANIES
  • 15.8.4 STARTING BLOCKS
• 15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.9.1 DETAILED LIST OF KEY STARTUPS/SMES
  • 15.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• 15.10 COMPETITIVE SCENARIO
  • 15.10.1 PRODUCT LAUNCHES AND APPROVALS

16 COMPANY PROFILE

• 16.1 KEY PLAYERS
  • 16.1.1 F. HOFFMANN-LA ROCHE
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches and approvals
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 DANAHER CORPORATION
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches and approvals
      • 16.1.2.3.2 Deals
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses and competitive threats
  • 16.1.3 THERMO FISHER SCIENTIFIC INC
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches and approvals
      • 16.1.3.3.2 Deals
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses and competitive threats
  • 16.1.4 ABBOTT LABORATORIES
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Deals
      • 16.1.4.3.2 Expansions
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses and competitive threats
  • 16.1.5 AGILENT TECHNOLOGIES INC.
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product launches and approvals
      • 16.1.5.3.2 Deals
      • 16.1.5.3.3 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses and competitive threats
  • 16.1.6 QIAGEN N.V.
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches and approvals
      • 16.1.6.3.2 Deals
      • 16.1.6.3.3 Expansions
    • 16.1.6.4 MnM view
      • 16.1.6.4.1 Right to win
      • 16.1.6.4.2 Strategic choices
      • 16.1.6.4.3 Weaknesses and competitive threats
  • 16.1.7 ILLUMINA, INC
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product launches and approvals
      • 16.1.7.3.2 Deals
      • 16.1.7.3.3 Expansions
    • 16.1.7.4 MnM view
      • 16.1.7.4.1 Right to win
      • 16.1.7.4.2 Strategic choices
      • 16.1.7.4.3 Weaknesses and competitive threats
  • 16.1.8 HOLOGIC, INC
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product launches and approvals
      • 16.1.8.3.2 Deals
      • 16.1.8.3.3 Expansions
    • 16.1.8.4 MnM view
      • 16.1.8.4.1 Right to win
      • 16.1.8.4.2 Strategic choices
      • 16.1.8.4.3 Weaknesses and competitive threats
  • 16.1.9 BECTON, DICKINSON AND COMPANY
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product launches and approvals
      • 16.1.9.3.2 Deals
    • 16.1.9.4 MnM view
      • 16.1.9.4.1 Right to win
      • 16.1.9.4.2 Strategic choices
      • 16.1.9.4.3 Weaknesses and competitive threats
  • 16.1.10 SIEMENS HEALTHINEERS AG
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product launches and approvals
      • 16.1.10.3.2 Expansions
    • 16.1.10.4 MnM view
      • 16.1.10.4.1 Right to win
      • 16.1.10.4.2 Strategic choices
      • 16.1.10.4.3 Weaknesses and competitive threats
  • 16.1.11 EXACT SCIENCES CORPORATION
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Product launches and approvals
      • 16.1.11.3.2 Deals
      • 16.1.11.3.3 Expansions
  • 16.1.12 GUARDANT HEALTH, INC
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Product launches and approvals
      • 16.1.12.3.2 Deals
  • 16.1.13 SYSMEX CORPORATION
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Expansions
  • 16.1.14 BIOMERIEUX SA.
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Product launches and approvals
  • 16.1.15 MYRIAD GENETICS, INC
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Product launches and approvals
      • 16.1.15.3.2 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 NEOGENOMICS, INC
  • 16.2.2 NATERA, INC
  • 16.2.3 TEMPUS AI, INC
  • 16.2.4 GRAIL, INC
  • 16.2.5 CARIS LIFE SCIENCES, INC, INC.
  • 16.2.6 PERSONALIS, INC
  • 16.2.7 DELFI DIAGNOSTICS, INC
  • 16.2.8 FULGENT GENETICS, INC
  • 16.2.9 BURNING ROCK BIOTECH LIMITED
  • 16.2.10 GENETRON HOLDINGS LIMITED

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
• 17.2 RESEARCH APPROACH
  • 17.2.1 SECONDARY RESEARCH
    • 17.2.1.1 Key data from secondary sources
  • 17.2.2 PRIMARY DATA
    • 17.2.2.1 Primary sources
    • 17.2.2.2 Key data from primary sources
    • 17.2.2.3 Key industry insights
• 17.3 MARKET SIZE ESTIMATION
  • 17.3.1 BOTTOM-UP APPROACH
    • 17.3.1.1 Approach 1: Company revenue estimation approach
    • 17.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 17.3.1.3 Growth forecast
  • 17.3.2 TOP-DOWN APPROACH
• 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 17.5 MARKET SHARE ANALYSIS
• 17.6 RESEARCH ASSUMPTIONS
  • 17.6.1 PARAMETRIC ASSUMPTIONS
  • 17.6.2 GROWTH RATE ASSUMPTIONS
• 17.7 RESEARCH LIMITATIONS
• 17.8 RISK ASSESSMENT

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS